| LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 |
1800 CONCORD PIKE, P.O. BOX 15437
| Address2 |
|
| City |
WILMINGTON
| State |
DE
| Zip Code |
19850
| Country |
USA
|
3. Principal place of business (if different than line 2)
| City |
| State |
| Zip Code |
| Country |
|
| 5. Senate ID# 54073-12
|
||||||||
| 6. House ID# 349750000
|
||||||||
| TYPE OF REPORT | 8. Year |
2011
| Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
| 11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
| Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature |
Digitally Signed By: Thomas F. Felton, Senior Counsel
| Date |
08/31/2011
|
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
HR 5 (Help Efficient, Accessible, Low-cost Timely Healthcare Act of 2011) - issues related medical malpractice reform
HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to development of antibiotics
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
|
Christie
|
Bloomquist
|
|
| |
|
Richard
|
Buckley
|
|
| |
|
Andrew
|
Kaplan
|
|
| |
|
Danny
|
Ly
|
|
| |
|
Kirsten
|
Powell
|
|
| |
|
Bradley
|
Rossin
|
|
| |
|
Heather
|
Strawn
|
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicare Part D Coverage Gap Program
HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicaid price reporting, rebate calculation, and expansion of eligible utilization
S. 1251 - issues related to Medicare fraud and abuse laws
HR 2190, S. 1206 - issues related to Medicare Part D rebates
HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform legislation and implementation, including the newly-created Independent Payment Advisory Board
HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152), HR 2248 - issues related to health care reform legislation and implementation, including proposed changes to the Medicare Program regarding pharmaceutical rebates and price negotiation
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
|
Christie
|
Bloomquist
|
|
| |
|
Richard
|
Buckley
|
|
| |
|
Bradley
|
Rossin
|
|
| |
|
Heather
|
Strawn
|
|
| |
|
Bela
|
Sastry
|
|
Office of Asst. Sec'y Planning & Evaluation
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
S. 27 (Preserve Access to Affordable Generics Act) - Legislative proposals surrounding patent reform and intellectual property issues, including patent settlements
S. 23, HR 1249 (America Invents Act) - legislative proposals regarding patent reform including "first to file" and "supplemental re-examination" issues
HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issuess related to the development of antibiotics
Participate in executive branch discussions regarding intellectual property issues arising in foreign countries
Discussions regarding global/free trade agreements and protection of intellectual property
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Commerce - Dept of (DOC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
|
Richard
|
Buckley
|
|
| |
|
Andrew
|
Kaplan
|
|
| |
|
Danny
|
Ly
|
|
| |
|
Bradley
|
Rossin
|
|
| |
|
Heather
|
Strawn
|
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
Legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer (anti-counterfeiting/anti-diversion efforts)
HR 2245, S. 296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages
S. 319 and related legislative proposals regarding prescriptiond drug importation and safety issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
|
Heather
|
Strawn
|
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) V (no bill number yet)
HR 2112, HR 2190, S1206 - Proposed legisalation regarding FDA appropriations
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
|
Richard
|
Buckley
|
|
| |
|
Andrew
|
Kaplan
|
|
| |
|
Danny
|
Ly
|
|
| |
|
Bradley
|
Rossin
|
|
| |
|
Heather
|
Strawn
|
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Issues related to reform of tax code and possible timing of any such reform bill (no bill number yet)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
|
Danny
|
Ly
|
|
| |
|
Andrew
|
Kaplan
|
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Trade Agreements Act and country or origin issues in government contracting (no bill number yet)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
|
Andrew
|
Kaplan
|
|
| |
|
Heather
|
Strawn
|
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code GOV
16. Specific lobbying issues
Monitoring developments regarding the Foreign Corrupt Practices Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
|
Heather
|
Strawn
|
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
| State |
| Zip Code |
| Country |
|
21. Client new principal place of business (if different than line 20)
| City |
| State |
| Zip Code |
| Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
| 13 |
|
||||||
| 2 |
| 14 |
|
||||||
| 3 |
| 15 |
|
||||||
| 4 |
| 16 |
|
||||||
| 5 |
| 17 |
|
||||||
| 6 |
| 18 |
|
||||||
| 7 |
| 19 |
|
||||||
| 8 |
| 20 |
|
||||||
| 9 |
| 21 |
|
||||||
| 10 |
| 22 |
|
||||||
| 11 |
| 23 |
|
||||||
| 12 |
| 24 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
|
||||||||||||||
|
|
|
|||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 7 | 13 |
| 2 | 8 | 14 |
| 3 | 9 | 15 |
| 4 | 10 | 16 |
| 5 | 11 | 17 |
| 6 | 12 | 18 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address | Principal place of business (city and state or country) | Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
|
||||||||||||||
| AstraZeneca AB |
|
| 0.00 | % | ||||||||||
| AstraZeneca Treasury Limited |
|
| 0.00 | % | ||||||||||
| AstraZeneca UK Limited |
|
| 0.00 | % | ||||||||||
| AstraZeneca Intermediate Holdings Ltd. |
|
| 0.00 | % | ||||||||||
| AstraZeneca PLC |
|
| 0.00 | % | ||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 13 | 25 |
| 2 | 14 | 26 |
| 3 | 15 | 27 |
| 4 | 16 | 28 |
| 5 | 17 | 29 |
| 6 | 18 | 30 |
| 7 | 19 | 31 |
| 8 | 20 | 32 |
| 9 | 21 | 33 |
| 10 | 22 | 34 |
| 11 | 23 | 35 |
| 12 | 24 | 36 |